There are a few S&P/ASX 200 Index (ASX: XJO) shares that are delivering elevated levels of growth at the moment.
COVID-19 has caused flow-on effects to different industries and companies. For some, like travel, it has made it difficult to make any profit at all. For others, there is a lot of growth happening:
Bapcor Ltd (ASX: BAP)
Bapcor describes itself as Asia Pacific’s leading provider of vehicle parts, accessories, equipment, services and solutions, with a network of over 1,100 locations across Australia and New Zealand.
The company had been guiding that the FY21 half-year result would be strong. It was.
Revenue for the six months to 31 December 2020 was up 25.8% to $883.6 million. Underlying earnings before interest, tax, depreciation and amortisation (EBITDA) grew by 36.5% to $145.6 million, underlying EBIT went up 45% to $106.8 million and underlying net profit after tax (NPAT) rose by 54% to $70.2.
Statutory earnings per share (EPS) rose 25.3% to 19.9 cents, allowing the board to increase the interim dividend by 12.5% to 9 cents.
Bapcor said that its trade segment, including Burson, delivered revenue growth of 12.3% and it added another 9 stores during the period.
The retail segment, which includes Autobarn, saw revenue growth of 44% and EBITDA growth of 55.8%.
The ASX 200 share also said that significant progress has been made in its investments for long-term growth. The new distribution warehouse in Melbourne is nearing completion and a new e-commerce platform will soon be launched.
It said that performance in the first month of the second half of FY21 has been at similar levels as the first six months of the year.
Sonic Healthcare Ltd (ASX: SHL)
Sonic is one of the world’s largest pathology businesses with operations in Australia, North America and Europe.
The healthcare ASX 200 share announced its FY21 half-year result a couple of days ago which showed revenue growth of 33% to $4.4 billion.
There has been a significant revenue and earnings contribution from COVID-19 testing, leveraging existing Sonic infrastructure. More than 18 million COVID-19 PCR tests have been performed to date in approximately 60 Sonic laboratories around the world.
The global base business revenue (excluding COVID-19 testing) was down 1% in the first half, but it was significantly less impacted than in the first few month of the pandemic.
Sonic said it managed to grow its profit margins in both its laboratory and imaging operations.
Half-year EBITDA grew by 89% to $1.3 billion and net profit rose by 166% to $678 million. It was this strength that allowed the board to continue the progressive dividend policy, increasing the dividend by 6% to 36 cents.
For the rest of FY21, it’s expecting continuing high levels of COVID-19 testing. It’s looking at growth opportunities globally – Sonic is currently bidding on “significant” opportunities in Australia, the UK, the USA and Canada.
Where to invest $1,000 right now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.
*Returns as of February 15th 2021
Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Bapcor. The Motley Fool Australia has recommended Sonic Healthcare Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
- ASX 200 rises above 7,000, Resolute Mining soars, Galaxy jumps – April 14, 2021 5:26pm
- Is it time to jump on the Westpac (ASX:WBC) share price? – April 14, 2021 3:49pm
- 2 quality ASX shares rated as top buys by brokers – April 14, 2021 2:51pm